Clinical Trial Contact Request

Substudy 02B: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With First Line (1L) Advanced Melanoma (MK-3475-02B/KEYMAKER-U02)

Please complete the form below to be contacted by our Clinical Trial Information Service
 (1024)
By submitting this form, you accept our Terms & Conditions and grant permission for us to contact you. We will not sell or share your information (Privacy Policy). Please do not submit another person’s name or email without his or her consent.